4gw5 - Revision history

OCA at 15:58, 14 March 2024

OCA — Thu, 14 Mar 2024 15:58:03 GMT

←Older revision		Revision as of 15:58, 14 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.2Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [https://pdbe.org/4gw5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [https://www.ebi.ac.uk/pdbsum/4gw5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4gw5 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [https://pdbe.org/4gw5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [https://www.ebi.ac.uk/pdbsum/4gw5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4gw5 ProSAT]</span></td></tr>
	</table>		</table>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging agents for medical applications. Herein, we present a unique peptide-binding site within the central cavity of the fragment antigen binding framework region of the chimeric, anti-epidermal growth factor receptor mAb cetuximab. We demonstrate through diffraction methods, biophysical studies, and sequence analysis that this peptide, a meditope, has moderate affinity for the Fab, is specific to cetuximab (i.e., does not bind to human IgGs), and has no significant effect on antigen binding. We further demonstrate by diffraction studies and biophysical methods that the meditope binding site can be grafted onto the anti-human epidermal growth factor receptor 2 mAb trastuzumab, and that the antigen binding affinity of the grafted trastuzumab is indistinguishable from the parental mAb. Finally, we demonstrate a bivalent meditope variant binds specifically and stably to antigen-bearing cells only in the presence of the meditope-enabled mAbs. Collectively, this finding and the subsequent characterization and engineering efforts indicate that this unique interface could serve as a noncovalent "linker" for any meditope-enabled mAb with applications in multiple mAb-based technologies including diagnostics, imaging, and therapeutic delivery.
-
-	Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.,Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC Proc Natl Acad Sci U S A. 2013 Oct 7. PMID:24101516<ref>PMID:24101516</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 4gw5" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]		*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 07:22, 26 October 2022

OCA — Wed, 26 Oct 2022 07:22:27 GMT

←Older revision		Revision as of 07:22, 26 October 2022
Line 3:		Line 3:
	<StructureSection load='4gw5' size='340' side='right'caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>		<StructureSection load='4gw5' size='340' side='right'caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Lk3_transgenic_mice Lk3 transgenic mice~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4gw1\|4gw1]]~~</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [https://pdbe.org/4gw5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [https://www.ebi.ac.uk/pdbsum/4gw5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4gw5 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [~~http~~://pdbe.org/4gw5 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4gw5 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4gw5 ProSAT]</span></td></tr>	+
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 17:		Line 16:
	</div>		</div>
	<div class="pdbe-citations 4gw5" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4gw5" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Lk3 transgenic mice~~]]	+	[[Category: Mus musculus]]
-	[[Category: Avery~~, K N~~]]	+	[[Category: Avery KN]]
-	[[Category: Bzymek~~, K P~~]]	+	[[Category: Bzymek KP]]
-	[[Category: Donaldson~~, J M~~]]	+	[[Category: Donaldson JM]]
-	[[Category: Horne~~, D A~~]]	+	[[Category: Horne DA]]
-	[[Category: Williams~~, J C~~]]	+	[[Category: Williams JC]]
-	[[Category: Zer, C]]	+	[[Category: Zer C]]
-	~~[[Category: Egfr]]~~	+
-	~~[[Category: Igg]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 09:33, 5 February 2020

OCA — Wed, 05 Feb 2020 09:33:37 GMT

←Older revision		Revision as of 09:33, 5 February 2020
Line 1:		Line 1:

	==cQYN meditope - Cetuximab Fab==		==cQYN meditope - Cetuximab Fab==
-	<StructureSection load='4gw5' size='340' side='right' caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>	+	<StructureSection load='4gw5' size='340' side='right'caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>
Line 21:		Line 21:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Lk3 transgenic mice]]		[[Category: Lk3 transgenic mice]]
	[[Category: Avery, K N]]		[[Category: Avery, K N]]

OCA at 17:04, 11 August 2016

OCA — Thu, 11 Aug 2016 17:04:57 GMT

←Older revision		Revision as of 17:04, 11 August 2016
Line 1:		Line 1:
		+
	==cQYN meditope - Cetuximab Fab==		==cQYN meditope - Cetuximab Fab==
	<StructureSection load='4gw5' size='340' side='right' caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>		<StructureSection load='4gw5' size='340' side='right' caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/~~9muri 9muri~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4gw1\|4gw1]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4gw1\|4gw1]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [http://www.ebi.ac.uk/pdbsum/4gw5 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [http://pdbe.org/4gw5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [http://www.ebi.ac.uk/pdbsum/4gw5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4gw5 ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 15:		Line 16:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4gw5" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Lk3 transgenic mice]]
	[[Category: Avery, K N]]		[[Category: Avery, K N]]
	[[Category: Bzymek, K P]]		[[Category: Bzymek, K P]]

OCA at 13:53, 4 January 2015

OCA — Sun, 04 Jan 2015 13:53:21 GMT

←Older revision		Revision as of 13:53, 4 January 2015
Line 1:		Line 1:
-	~~{{STRUCTURE_4gw5~~\| ~~PDB~~=4gw5 \| ~~SCENE~~= }}	+	==cQYN meditope - Cetuximab Fab==
-	===~~cQYN meditope~~ - ~~Cetuximab Fab~~===	+	<StructureSection load='4gw5' size='340' side='right' caption='[[4gw5]], [[Resolution\|resolution]] 2.20Å' scene=''>
-	~~{{ABSTRACT_PUBMED_24101516}}~~	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/9muri 9muri]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4GW5 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4gw1\|4gw1]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4gw5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gw5 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4gw5 RCSB], [http://www.ebi.ac.uk/pdbsum/4gw5 PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging agents for medical applications. Herein, we present a unique peptide-binding site within the central cavity of the fragment antigen binding framework region of the chimeric, anti-epidermal growth factor receptor mAb cetuximab. We demonstrate through diffraction methods, biophysical studies, and sequence analysis that this peptide, a meditope, has moderate affinity for the Fab, is specific to cetuximab (i.e., does not bind to human IgGs), and has no significant effect on antigen binding. We further demonstrate by diffraction studies and biophysical methods that the meditope binding site can be grafted onto the anti-human epidermal growth factor receptor 2 mAb trastuzumab, and that the antigen binding affinity of the grafted trastuzumab is indistinguishable from the parental mAb. Finally, we demonstrate a bivalent meditope variant binds specifically and stably to antigen-bearing cells only in the presence of the meditope-enabled mAbs. Collectively, this finding and the subsequent characterization and engineering efforts indicate that this unique interface could serve as a noncovalent "linker" for any meditope-enabled mAb with applications in multiple mAb-based technologies including diagnostics, imaging, and therapeutic delivery.

-	~~==About this Structure==~~	+	Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.,Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC Proc Natl Acad Sci U S A. 2013 Oct 7. PMID:24101516<ref>PMID:24101516</ref>
-	~~[[4gw5]] is~~ a ~~6 chain structure with sequence from [http://en~~.~~wikipedia~~.~~org/wiki/9muri 9muri]~~. ~~Full crystallographic information is available from [http~~:/~~/oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].~~	+

-	==~~Reference~~==	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~<ref group="xtra">PMID:024101516</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	</div>
-	~~[[Category: 9muri]]~~	+	== References ==
-	[[Category: Avery, K N.]]	+	<references/>
-	[[Category: Bzymek, K P.]]	+	__TOC__
-	[[Category: Donaldson, J M.]]	+	</StructureSection>
-	[[Category: Horne, D A.]]	+	[[Category: Avery, K N]]
-	[[Category: Williams, J C.]]	+	[[Category: Bzymek, K P]]
-	[[Category: Zer, C.]]	+	[[Category: Donaldson, J M]]
		+	[[Category: Horne, D A]]
		+	[[Category: Williams, J C]]
		+	[[Category: Zer, C]]
	[[Category: Egfr]]		[[Category: Egfr]]
	[[Category: Igg]]		[[Category: Igg]]
	[[Category: Immune system]]		[[Category: Immune system]]

OCA at 04:47, 9 April 2014

OCA — Wed, 09 Apr 2014 04:47:07 GMT

←Older revision		Revision as of 04:47, 9 April 2014
Line 4:		Line 4:

	==About this Structure==		==About this Structure==
-	[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/ ~~] and [http://en.wikipedia.org/wiki/Zasmidium_angulare Zasmidium angulare~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].	+	[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/9muri 9muri]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].

	==Reference==		==Reference==
	<ref group="xtra">PMID:024101516</ref><references group="xtra"/><references/>		<ref group="xtra">PMID:024101516</ref><references group="xtra"/><references/>
-	[[Category: ~~Zasmidium angulare~~]]	+	[[Category: 9muri]]
	[[Category: Avery, K N.]]		[[Category: Avery, K N.]]
	[[Category: Bzymek, K P.]]		[[Category: Bzymek, K P.]]

OCA at 05:12, 23 October 2013

OCA — Wed, 23 Oct 2013 05:12:13 GMT

←Older revision		Revision as of 05:12, 23 October 2013
Line 1:		Line 1:
	{{STRUCTURE_4gw5\| PDB=4gw5 \| SCENE= }}		{{STRUCTURE_4gw5\| PDB=4gw5 \| SCENE= }}
	===cQYN meditope - Cetuximab Fab===		===cQYN meditope - Cetuximab Fab===
		+	{{ABSTRACT_PUBMED_24101516}}

	==About this Structure==		==About this Structure==
	[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Zasmidium_angulare Zasmidium angulare]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].		[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Zasmidium_angulare Zasmidium angulare]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:024101516</ref><references group="xtra"/><references/>
	[[Category: Zasmidium angulare]]		[[Category: Zasmidium angulare]]
	[[Category: Avery, K N.]]		[[Category: Avery, K N.]]

OCA at 06:36, 10 October 2013

OCA — Thu, 10 Oct 2013 06:36:19 GMT

←Older revision		Revision as of 06:36, 10 October 2013
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	{{STRUCTURE_4gw5\| PDB=4gw5 \| SCENE= }}
		+	===cQYN meditope - Cetuximab Fab===

-	~~The entry~~ 4gw5 is ~~ON HOLD until Mar 01 2015~~	+	==About this Structure==
-		+	[[4gw5]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Zasmidium_angulare Zasmidium angulare]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4GW5 OCA].
-	~~Authors~~: ~~Donaldson, J~~.M.~~, Zer, C~~., Avery, K.N., Bzymek, K.P., Horne, D.A., Williams, J.C.	+	[[Category: Zasmidium angulare]]
-		+	[[Category: Avery, K N.]]
-	~~Description~~: ~~cQYN meditope -Cetuximab Fab~~	+	[[Category: Bzymek, K P.]]
		+	[[Category: Donaldson, J M.]]
		+	[[Category: Horne, D A.]]
		+	[[Category: Williams, J C.]]
		+	[[Category: Zer, C.]]
		+	[[Category: Egfr]]
		+	[[Category: Igg]]
		+	[[Category: Immune system]]

OCA at 04:42, 18 July 2013

OCA — Thu, 18 Jul 2013 04:42:06 GMT

←Older revision		Revision as of 04:42, 18 July 2013
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4gw5 is ON HOLD until ~~Paper Publication~~	+	The entry 4gw5 is ON HOLD until Mar 01 2015

	Authors: Donaldson, J.M., Zer, C., Avery, K.N., Bzymek, K.P., Horne, D.A., Williams, J.C.		Authors: Donaldson, J.M., Zer, C., Avery, K.N., Bzymek, K.P., Horne, D.A., Williams, J.C.

	Description: cQYN meditope -Cetuximab Fab		Description: cQYN meditope -Cetuximab Fab

OCA at 13:18, 20 February 2013

OCA — Wed, 20 Feb 2013 13:18:53 GMT

←Older revision		Revision as of 13:18, 20 February 2013
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4gw5 is ON HOLD	+	The entry 4gw5 is ON HOLD until Paper Publication

	Authors: Donaldson, J.M., Zer, C., Avery, K.N., Bzymek, K.P., Horne, D.A., Williams, J.C.		Authors: Donaldson, J.M., Zer, C., Avery, K.N., Bzymek, K.P., Horne, D.A., Williams, J.C.

	Description: cQYN meditope -Cetuximab Fab		Description: cQYN meditope -Cetuximab Fab